Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

EarningsVyepti®Positive

AI Analysis

Summary

Lundbeck reported H1 2026 total revenue growth of +16% CER (DKK 13,588 million) driven by strong Vyepti® performance and commercial execution in the U.S. and Europe.

Financial Highlights

Revenue

DKK 13,588 million

Importance:5/10

Sentiment:

0.70

earningsrevenue growthcommercial executionH1 2026

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on August 19, 2026 5:59 AM

Read Original